File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Sofosbuvir/Velpatasvir fixed dose combination for 12 weeks in hcv infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 Study)

TitleSofosbuvir/Velpatasvir fixed dose combination for 12 weeks in hcv infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 Study)
Authors
Asselah, TShafran, SBourgeois, SLai, CLCramp, MMathurin, PWillems, BNguyen, MHDavis, MNHuang, KCSvarovskaia, EOsinusi, AMcnally, JBrainard, DMcHutchison, JShaikh, OSTran, TT
Issue Date2016
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S827-S828, abstract no. SAT-279 How to Cite?
DOI: http://dx.doi.org/10.1016/S0168-8278(16)01619-6
AbstractBACKGROUND AND AIMS: The once-daily fixed-dose combination (FDC) tablet of sofosbuvir/velpatasvir (SOF/VEL) has demonstrated high efficacy in genotypes 1–6 HCV-infected patients when administered for 12 weeks. This analysis describes the safety and efficacy of SOF/VEL FDC in patients previously treated with SOF/VEL placebo in the phase 3 registrational, ASTRAL-1 study …
DescriptionPoster Presentations - Preliminary results of retrospective single center experience: no. SAT-279
Persistent Identifierhttp://hdl.handle.net/10722/234187
ISSN
0168-8278
2023 Impact Factor: 26.8
2023 SCImago Journal Rankings: 9.857

 

DC FieldValueLanguage
dc.contributor.authorAsselah, T-
dc.contributor.authorShafran, S-
dc.contributor.authorBourgeois, S-
dc.contributor.authorLai, CL-
dc.contributor.authorCramp, M-
dc.contributor.authorMathurin, P-
dc.contributor.authorWillems, B-
dc.contributor.authorNguyen, MH-
dc.contributor.authorDavis, MN-
dc.contributor.authorHuang, KC-
dc.contributor.authorSvarovskaia, E-
dc.contributor.authorOsinusi, A-
dc.contributor.authorMcnally, J-
dc.contributor.authorBrainard, D-
dc.contributor.authorMcHutchison, J-
dc.contributor.authorShaikh, OS-
dc.contributor.authorTran, TT-
dc.date.accessioned2016-10-14T06:59:41Z-
dc.date.available2016-10-14T06:59:41Z-
dc.date.issued2016-
dc.identifier.citationThe International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S827-S828, abstract no. SAT-279-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/234187-
dc.descriptionPoster Presentations - Preliminary results of retrospective single center experience: no. SAT-279-
dc.description.abstractBACKGROUND AND AIMS: The once-daily fixed-dose combination (FDC) tablet of sofosbuvir/velpatasvir (SOF/VEL) has demonstrated high efficacy in genotypes 1–6 HCV-infected patients when administered for 12 weeks. This analysis describes the safety and efficacy of SOF/VEL FDC in patients previously treated with SOF/VEL placebo in the phase 3 registrational, ASTRAL-1 study …-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.rights© 2016 This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleSofosbuvir/Velpatasvir fixed dose combination for 12 weeks in hcv infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 Study)-
dc.typeConference_Paper-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.doi10.1016/S0168-8278(16)01619-6-
dc.identifier.hkuros267701-
dc.identifier.volume64-
dc.identifier.issue2 suppl.-
dc.identifier.spageS827, abstract no. SAT-279-
dc.identifier.epageS828-
dc.publisher.placeThe Netherlands-
dc.identifier.issnl0168-8278-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats